• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两性霉素B盘状脂质体:一种口服给药载体。

Amphotericin B cochleates: a vehicle for oral delivery.

作者信息

Perlin David S

机构信息

Public Health Research Institute, International Center for Public Health, 225 Warren Street, Newark, NJ 07103, USA.

出版信息

Curr Opin Investig Drugs. 2004 Feb;5(2):198-201.

PMID:15043394
Abstract

Cochleates are a novel lipid-based delivery vehicle consisting of crystalline phospholipid-cation structures that form spiral lipid sheets. They represent a new technology platform for oral delivery of clinically important drugs that possess poor oral bioavailability. Orally administered cochleates containing amphotericin B (CAMB) showed broad-spectrum activity in murine infection models of candidiasis, aspergillosis and cryptococcosis. Initial biodistribution studies of CAMB administered orally in mice demonstrated that cochleates delivered significant levels of AMB to target organs. The lipid particulate nature of cochleates also imparted reduced toxicity that mimics other lipid-amphotericin B complexes. Cochleates are a promising new vehicle for oral delivery of amphotericin B at therapeutic levels.

摘要

耳蜗形脂质体是一种新型的基于脂质的给药载体,由形成螺旋脂质片的结晶磷脂 - 阳离子结构组成。它们代表了一种新技术平台,用于口服递送口服生物利用度差的临床重要药物。口服含两性霉素B的耳蜗形脂质体(CAMB)在念珠菌病、曲霉病和隐球菌病的小鼠感染模型中显示出广谱活性。对口服给予小鼠的CAMB进行的初步生物分布研究表明,耳蜗形脂质体将大量的两性霉素B递送至靶器官。耳蜗形脂质体的脂质颗粒性质还降低了毒性,这与其他脂质 - 两性霉素B复合物类似。耳蜗形脂质体是一种有前景的新型载体,可用于以治疗水平口服递送两性霉素B。

相似文献

1
Amphotericin B cochleates: a vehicle for oral delivery.两性霉素B盘状脂质体:一种口服给药载体。
Curr Opin Investig Drugs. 2004 Feb;5(2):198-201.
2
Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.口服卷曲两性霉素B在系统性念珠菌病小鼠模型中的疗效。
Antimicrob Agents Chemother. 2000 Sep;44(9):2356-60. doi: 10.1128/AAC.44.9.2356-2360.2000.
3
Drug delivery by lipid cochleates.脂质耳蜗形囊泡介导的药物递送
Methods Enzymol. 2005;391:314-29. doi: 10.1016/S0076-6879(05)91018-5.
4
Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model.两性霉素B盘状小体对小鼠模型白色念珠菌感染的抗真菌活性。
Antimicrob Agents Chemother. 2000 Jun;44(6):1463-9. doi: 10.1128/AAC.44.6.1463-1469.2000.
5
[Anti-infectious effect of sustained antravitreal amphotericin B drug delivery system on experimental rabbit fungal endophthalmitis of Candida albicans].[玻璃体内持续递送两性霉素B给药系统对实验性白色念珠菌性兔真菌性眼内炎的抗感染作用]
Zhonghua Yan Ke Za Zhi. 2006 May;42(5):420-5.
6
The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.两性霉素B的重新配方用于口服治疗系统性真菌感染和内脏利什曼病。
Expert Opin Drug Deliv. 2009 Mar;6(3):271-84. doi: 10.1517/17425240902802861.
7
In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.新型两性霉素B多聚体剂型的体内分布及治疗效果
J Antimicrob Chemother. 2008 May;61(5):1125-31. doi: 10.1093/jac/dkn048. Epub 2008 Feb 19.
8
Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis.含两性霉素B的口服耳蜗脂质体在小鼠曲霉病模型中的疗效。
Antimicrob Agents Chemother. 2002 Aug;46(8):2704-7. doi: 10.1128/AAC.46.8.2704-2707.2002.
9
Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.聚集体两性霉素B不同给药方案的疗效
Int J Antimicrob Agents. 2008 Jul;32(1):55-61. doi: 10.1016/j.ijantimicag.2008.02.025. Epub 2008 Jun 4.
10
Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.
J Pharm Sci. 2002 Aug;91(8):1827-37. doi: 10.1002/jps.10173.

引用本文的文献

1
Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.脂质体两性霉素B治疗利什曼病:从关键物理化学特性的鉴定到有效局部和口服制剂的设计
Pharmaceutics. 2022 Dec 28;15(1):99. doi: 10.3390/pharmaceutics15010099.
2
Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application.用于临床口服的两性霉素 B 的潜在基于脂质的策略。
Drug Deliv. 2023 Dec;30(1):2161671. doi: 10.1080/10717544.2022.2161671.
3
Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis.
耳蜗内两性霉素 B 在小鼠和人体黏膜念珠菌病中的疗效。
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0030822. doi: 10.1128/aac.00308-22. Epub 2022 Jun 14.
4
Design of amphotericin B oral formulation for antifungal therapy.用于抗真菌治疗的两性霉素B口服制剂的设计
Drug Deliv. 2017 Nov;24(1):1-9. doi: 10.1080/10717544.2016.1225852.
5
Chitosan functionalized nanocochleates for enhanced oral absorption of cyclosporine A.壳聚糖功能化纳米耳蜗用于增强环孢素 A 的口服吸收。
Sci Rep. 2017 Jan 23;7:41322. doi: 10.1038/srep41322.
6
Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection.评估 cubosomal 纳米粒作为口服 delivery 两性霉素 B 治疗真菌感染的潜力。
Int J Nanomedicine. 2014;9:327-36. doi: 10.2147/IJN.S54967. Epub 2014 Jan 6.